Requests for this Liquid Biopsy NGS Panel are Soaring

Written by: Anna Israyelyan, MD, PhD
Manager, Biopharma Solutions

Published on:
December 5th, 2017

Anna Israyelyan, MD, PhD
Dr. Israyelyan joined CGI in 2015. She has over 15 years of extensive cancer research and management experience in industry and academia covering wide range of medical areas, including basic, translational, and clinical research. Anna is an active member of the American Society of Hematology (ASH), the American Association for Cancer Research (AACR), and American Association for the Advancement of Science (AAAS). Dr. Israyelyan has a scientific advisory role with matrix management of scientific, technical, and operational aspects related to various biopharma projects and collaborations involving biomarkers in solid tumors and hematologic malignancies.

Liquid biopsy is an increasingly hot topic in oncology today and is rapidly emerging as an important tool for precision medicine…

The term “liquid biopsy” refers to the minimally invasive sampling and molecular analysis of body liquids, primarily blood, as a diagnostic and monitoring tool for diseases such as cancer. It is a simple alternative to costly and invasive surgical biopsies and procedures, giving physicians an idea about which treatments are most likely to work for each patient.

In a previous Shared Insight post, we shared with you the details of our CLIA-validated and commercially launched next generation sequencing (NGS) liquid biopsy assay, Liquid::Lung-cfDNA™, which detects lung tumor-derived cell-free DNA (cfDNA) obtained from the plasma fraction of blood. We have also talked about CGI’s other liquid biopsy options we currently deploy for clinical trial monitoring. One in particular we would like to feature today is Archer’s Reveal ctDNA™ 28.

As you may know, CGI subscribes to technology- and platform-agnostic philosophy to providing the best scientific solutions to our biopharma clients. For this reason, CGI became one of the first Certified Service Providers for ArcherDx. We were so excited about the chemistry; we wanted to make it available to our clients. In fact, many of our clients were proactively requesting we make these assays available in our lab.

Of the extensive ArcherDx menu, the company’s Reveal ctDNA™ 28 liquid biopsy mutation profiling assay has garnered the most attention and witnessed the most uptake from our client portfolio. Archer® Reveal ctDNA™ 28 is an advanced and user-friendly solution for targeted NGS of circulating cell-free tumor DNA (ccfDNA/cfDNA/ctDNA) from 28 genes commonly found mutated in solid tumors.


*Full exon coverage

Additional Reveal ctDNA™ 28 highlights include:

  • Relevant fragment capture Anchored Multiplex PCR (AMP™)-based target enrichment preferentially enriches for highly fragmented ctDNA fragments over genomic cfDNA to reduce background and increase detection sensitivity of low-allelic frequency (AF) mutations
  • Single-day library prep NGS-ready libraries can be prepared in under 8 hours with less than 1 hour of hands-on time, providing sequencing results in as little as 3 days
  • Error correction and quantitative analysis unique molecular barcode sequences ligated prior to amplification enable duplicate read binning and advanced error correction for confident variant calls
  • Sensitive and robust variant detection Reliably detect high-AF (5%) variants using as little as 5ng total cfDNA input and low AF (1%) variants from as little as 10ng

Additionally, one of the compelling attributes of working with ArcherDx as a Certified Service Provider is the flexibility, willingness, and rapid response to developing and integrating custom content into its menu. This collaborative approach is a differentiator for the company, as important as its proprietary chemistry.

Utilizing the Archer® technology, it is also possible to do paired multiplex analysis of formalin-fixed paraffin-embedded (FFPE) and liquid biopsy samples. The Archer Reveal ctDNA 28 Concordance Kit combines Archer VariantPlex™ with Reveal ctDNA™ 28 for powerful copy number and variant detection from solid tumors and sensitive mutation detection from ctDNA, respectively.

To learn more about Archer® assays or any of our comprehensive test and technology platforms, email me today.